Goswami Jyotirup, Manir Kazi S, Mondal Monidipa, Mallik Suman, Das Sayan, Sen Arijit, Pal Bipasha, Das Suresh, Palit Soura, Sarkar Papai
Radiation Oncology Department, Narayana Superspeciality Hospital, Andul Road, Howrah, West Bengal 711103, India.
Gynecol Oncol Rep. 2021 Jun 24;37:100822. doi: 10.1016/j.gore.2021.100822. eCollection 2021 Aug.
Recent image-guided brachytherapy data suggests, dose-escalation to a cumulative EQD2 (equivalent dose delivered at 2 Gy/#) of ≥87 Gy is associated with significantly better disease control. We present a clinical audit of a pragmatic radical radiotherapy protocol for advanced cervical cancer, using fewer fractions of brachytherapy than in the presently most popular protocol.
MATERIAL & METHODS: Between July 2015 and December 2018, 96 consecutive advanced cervical carcinoma patients were treated by pelvic external beam radiotherapy (EBRT) (50 Gy/25fractions/5 weeks) ± weekly intravenous chemotherapy followed by image guided high dose rate (HDR) brachytherapy, using intracavitary/interstitial/hybrid techniques (intended point A dose: 8 Gy/fractions) × 3 fractions (cumulative target EQD2 ≥ 86 Gy). Insertion was done individually for each fraction of treatment.
All patients completed their intended radiation protocol. 93.8% patients achieved complete response, while 6.2% patients achieved only partial response; no patients had stable/progressive disease. Out of the patients with partial response, 4.2% (4 out of 5 cases) cases of central/nodal residual disease underwent salvage surgery. At a median follow up of 21 months, 8.3% (8) patients had local failure, 1.1% (1) had nodal failure and 3.1% (3) had distant failures. Median Failure Free Survival was 29 months (26.5-31.5 months). On follow up, 6.3% and 3.2% patients had grade 2 or worse rectal and bladder morbidities respectively.
The protocol under study has been safe and effective in achieving dose-escalated radical chemoradiation in advanced cervical carcinoma. The use of fewer insertions of brachytherapy is logistically easier & can also be expected to improve compliance.
近期图像引导近距离放射治疗数据表明,累积等效生物剂量(EQD2,以2Gy/分次剂量计算的等效剂量)增加至≥87Gy与显著更好的疾病控制相关。我们对一种晚期宫颈癌实用根治性放疗方案进行了临床审计,该方案使用的近距离放射治疗分次比目前最流行的方案更少。
2015年7月至2018年12月期间,96例连续的晚期宫颈癌患者接受了盆腔外照射放疗(EBRT)(50Gy/25分次/5周)±每周静脉化疗,随后采用图像引导高剂量率(HDR)近距离放射治疗,使用腔内/组织间/混合技术(靶区A点剂量:8Gy/分次)×3分次(累积靶区EQD2≥86Gy)。每次治疗分次均单独进行插植。
所有患者均完成了预定的放疗方案。93.8%的患者达到完全缓解,而6.2%的患者仅达到部分缓解;无患者病情稳定/进展。在部分缓解的患者中,4.2%(5例中的4例)中央/淋巴结残留病患者接受了挽救性手术。中位随访21个月时,8.3%(8例)患者出现局部复发,1.1%(1例)出现淋巴结复发,3.1%(3例)出现远处复发。无复发生存期的中位数为29个月(26.5 - 31.5个月)。随访时,分别有6.3%和3.2%的患者出现2级或更严重的直肠和膀胱并发症。
本研究中的方案在晚期宫颈癌中实现剂量递增的根治性放化疗方面是安全有效的。减少近距离放射治疗的插植次数在操作上更简便,并且预计还能提高依从性。